Epoch-cyclosporin A induces high response rates in relapsed lymphomas.
Lopez-Picazo
J M
JM
Gonzalez Manzano
R
R
Ordoñez Tres
J M
JM
Jimenez
M M
MM
Calvo
J P
JP
Brugarolas
A
A
D000206:Actuarial Analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D016572:Cyclosporine / Q000008:administration & dosage* / Q000494:pharmacology / Q000633:toxicity; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D018432:Drug Resistance, Multiple; D005047:Etoposide / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy*; D008297:Male; D010865:Pilot Projects; D011241:Prednisone / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D012008:Recurrence; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity
D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D016572:Cyclosporine; D003520:Cyclophosphamide; D011241:Prednisone